BREAST CANCER BASE

Research found that the use of estrogen and progesterone hormone replacement therapy for a breast cancer can increase the incidence of breast cancer twice.

Fred Hutchinson Cancer Research Center in Seattle, scientists above the age of 50 at least 537 patients with breast cancer were studied, their sick time in 1988-1990. Then they did not have the same 492 female breast cancer were compared. Scientists found that combination therapy for at least 6 months (average 4 years) with the incidence of lobular breast cancer is another group of patients was 2.6 times more.

Recently in Beijing at the 2003 new breast cancer treatment at the seminar, from the United States BaylorSammons breast cancer experts in the center released by the Center for metastatic breast cancer in combination with chemotherapy in patients with the latest research findings.

The study of 529 untreated metastatic breast cancer patients, before the transfer have received anthracycline-based drug treatment. The study will be divided into two groups in all cases, a group of 267 patients who received Gemzar / Taxol combination with chemotherapy for a 21-day cycle; The remaining patients to accept another group of single-drug paclitaxel chemotherapy, treatment continued until disease progression or the emergence of tolerance of side effects. The results showed that combination chemotherapy group that the median time to progression was 5.4 months, Taxol alone group to 3.5 months. In addition, the United chemotherapy group over 50% of patients without disease progression time is six months.